415 Capital | Activity | F4

415 Capital Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

14 milestones· OCT 2025 – SEP 2026Show all

Milestone

Portfolio company ReEmerge exited stealth with an oversubscribed $37M Series A to advance deep brain stimulation for cognitive deficits from traumatic brain injury.

ReEmerge

ReEmerge 415 Capital

415capital.comSEP 15, 2026

SEP 15, 2026

Milestone

Portfolio company R3 Vascular expanded its management team with two senior executives.

R3 Vascular

R3 Vascular 415 Capital

415capital.comAUG 24, 2026

AUG 24, 2026

Milestone

Portfolio company Distalmotion received FDA 510(k) clearance for ventral hernia repair on its DEXTER robotic surgery system.

Distal Motion

Distal Motion 415 Capital

415capital.comAUG 13, 2026

AUG 13, 2026

Milestone

Portfolio company Hilo launched new wearable blood pressure monitoring technology.

HiLo

HiLo 415 Capital

415capital.comJUL 21, 2026

JUL 21, 2026

Milestone

Portfolio company TRiCares announced initiation of its TRICURE US IDE pivotal study for the Topaz tricuspid valve replacement system.

TRiCares

TRiCares 415 Capital

415capital.comJUL 9, 2026

JUL 9, 2026

Milestone

Portfolio company Distalmotion received additional US FDA 510(k) clearance for gynecology indications.

Distal Motion

Distal Motion 415 Capital

415capital.comJUN 16, 2026

JUN 16, 2026

Milestone

Portfolio company CorFlow Therapeutics completed Phase 1 and enrolled first patients in Phase 2 of its MOCA II pivotal trial, and gained approval to start the REVITALISE RCT in Europe.

CorFlow Therapeutics

CorFlow Therapeutics 415 Capital

415capital.comAPR 30, 2026

APR 30, 2026

Milestone

Portfolio company Supira Medical announced FDA approval for its SUPPORT II pivotal trial and appointed D. Keith Grossman to its board of directors.

Supira Medical

Supira Medical 415 Capital

415capital.comAPR 8, 2026

APR 8, 2026

Milestone

Portfolio company Endovascular Engineering (E2) raised an $80 million Series C to advance its next-generation thrombectomy platform.

Endovascular Engineering

Endovascular Engineering 415 Capital

415capital.comAPR 7, 2026

APR 7, 2026

Milestone

Portfolio company TRiCares received FDA approval for its TRICURE US IDE pivotal trial.

TRiCares

TRiCares 415 Capital

415capital.comAPR 7, 2026

APR 7, 2026

Milestone

Portfolio company TRiCares entered into a €20 million loan agreement with the European Investment Bank.

TRiCares

TRiCares 415 Capital

415capital.comJAN 20, 2026

JAN 20, 2026

Milestone

Portfolio company TRiCares completed its first TC-L 55mm Topaz implant in the ongoing TRICURE EU pivotal study.

TRiCares

TRiCares 415 Capital

415capital.comNOV 6, 2025

NOV 6, 2025

Milestone

Portfolio company Endovascular Engineering (E2) presented its ENGULF pivotal study as a late-breaking clinical trial at the VIVA Conference.

Endovascular Engineering

Endovascular Engineering 415 Capital

415capital.comNOV 3, 2025

NOV 3, 2025

Milestone

Portfolio company Distalmotion secured its third FDA clearance for DEXTER, adding a hysterectomy indication.

Distal Motion

Distal Motion 415 Capital

415capital.comOCT 1, 2025

OCT 1, 2025

Page 1 of 2